Related Experiment Video
Updated: Jul 9, 2025
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Applications of lung cancer organoids in precision medicine: from bench to bedside
Huihui Li1,2, Zexin Chen3, Ning Chen1,4
1Department of Medical Thoracic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Abstract:
As the leading cause of cancer-related mortality, lung cancer continues to pose a menacing threat to human health worldwide. Lung cancer treatment options primarily rely on chemoradiotherapy, surgery, targeted therapy, or immunotherapy. Despite significant progress in research and treatment, the 5-year survival rate for lung cancer patients is only 10-20%. There is an urgent need to develop more reliable preclinical models and valid therapeutic approaches. Patient-derived organoids with highly reduced tumour heterogeneity have emerged as a promising model for high-throughput drug screening to guide treatment of lung cancer patients. Organoid technology offers a novel platform for disease modelling, biobanking and drug development. The expected benefit of organoids is for cancer patients as the subsequent precision medicine technology. Over the past few years, numerous basic and clinical studies have been conducted on lung cancer organoids, highlighting the significant contributions of this technique. This review comprehensively examines the current state-of-the-art technologies and applications relevant to the formation of lung cancer organoids, as well as the potential of organoids in precision medicine and drug testing. Video Abstract.
Insights
Lung cancer organoids offer a promising preclinical model for high-throughput drug screening. This technology aids in developing personalized lung cancer treatments and improving patient survival rates.
Area of Science:
- Oncology
- Biotechnology
- Genomics
Background:
- Lung cancer remains a leading cause of cancer mortality globally.
- Current treatments have limited efficacy, with a 5-year survival rate of 10-20%.
- There is a critical need for improved preclinical models and therapeutic strategies.
Purpose of the Study:
- To review the current state-of-the-art technologies for lung cancer organoid formation.
- To examine the applications of organoids in precision medicine and drug testing for lung cancer.
- To highlight the potential of organoids in addressing unmet needs in lung cancer treatment.
Main Methods:
- Review of recent scientific literature on lung cancer organoid technology.
- Analysis of organoid formation techniques and their relevance.
- Evaluation of organoid applications in drug screening and personalized medicine.
Main Results:
- Patient-derived organoids effectively model tumor heterogeneity.
- Organoids provide a platform for high-throughput drug screening.
- Organoid technology shows significant potential for advancing lung cancer precision medicine.
Conclusions:
- Lung cancer organoids represent a significant advancement in preclinical research.
- Organoid technology facilitates personalized treatment strategies and drug development.
- Further research and clinical application of organoids are expected to improve lung cancer patient outcomes.
